scholarly journals Nasal‐alar invasive cutaneous aspergillosis in a patient with anaplastic astrocytoma: A case report

2021 ◽  
Author(s):  
Adham A. Aljariri ◽  
Ahmed Shaikh ◽  
Abdulqadir J. Nashwan ◽  
Mahir A. Petkar ◽  
Shanmugam Ganesan
2020 ◽  
Author(s):  
Adham Aljariri ◽  
Abdulqadir Nashwan ◽  
Ahmed Shaikh ◽  
Mahir Petkar ◽  
Shanmugam Ganesan

2013 ◽  
Vol 74 (S 01) ◽  
pp. e203-e206 ◽  
Author(s):  
Benjamin Brokinkel ◽  
Otmar Schober ◽  
Christian Ewelt ◽  
Walter Heindel ◽  
Gunnar Hargus ◽  
...  

2018 ◽  
Vol 115 ◽  
pp. 181-185
Author(s):  
Hidehiro Kohzuki ◽  
Masahide Matsuda ◽  
Shunichiro Miki ◽  
Makoto Shibuya ◽  
Eiichi Ishikawa ◽  
...  

2011 ◽  
Vol 29 (2) ◽  
pp. 107-112 ◽  
Author(s):  
Shinji Yamashita ◽  
Shinitsu Ryu ◽  
Shiro Miyata ◽  
Syunrou Uchinokura ◽  
Kiyotaka Yokogami ◽  
...  

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii444-iii444
Author(s):  
Erin Wright ◽  
Alexis Judd ◽  
Jennifer Stanke ◽  
Sarah Rush ◽  
Daniel Pettee

Abstract Congenital mismatch repair deficiency (CMMRD) is a pediatric cancer predisposition syndrome secondary to biallelic mutations in mismatch repair genes including MLH1, MSH2, MSH6, and PMS2. Due to the resulting lack of repair mechanisms, these patients develop a high intracellular mutational burden and have a high risk of development of multiple malignancies at a young age. Similar to patients with Lynch Syndrome (monoallelic mutations in MMR genes), these patients are at risk for development of central nervous system (CNS) tumors including high grade gliomas. Forty-eight percent of patients with CMMRD are diagnosed with a CNS malignancy. In this interesting case, a patient developed three metachronous malignancies prior to the age of 13, including Burkitt lymphoma, T-Cell lymphoma and anaplastic astrocytoma. Genomic analysis revealed a high mutational burden in his initial tumors, with multiple oncogenic mutations, as well as a previously unreported germline compound heterozygous MSH6 E744fs*12 and R248fs*8 alteration. He received a gross total resection of the tumor which in previous studies has been shown to have the highest impact on survival. Surgery was followed by radiation and ongoing treatment with an immune checkpoint inhibitor with stable disease at 6 months. The purpose of this case report is to describe the interesting presentation of CMMRD and discuss the previously unreported biallelic MSH6 mutations.


BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Ema Kantorová ◽  
Michal Bittšanský ◽  
Štefan Sivák ◽  
Eva Baranovičová ◽  
Petra Hnilicová ◽  
...  

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi99-vi99
Author(s):  
Kyu Sang Lee ◽  
Gheeyoung Choe

Abstract Primary glioblastoma develops de novo without clinical or histological evidence of a low-grade precursor lesion, while secondary glioblastoma develops from a low-grade glioma. The same IDH mutation is observed in almost secondary glioblastomas that occurs in low-grade gliomas with IDH mutation. Present report is an extraordinary case of secondary glioblastoma, IDH-wildtype arising in diffuse astrocytoma, IDH-mutant. A 31-year-old female presented with seizure 3 months ago, who had a history of operation for diffuse astrocytoma, IDH-mutant on the left frontal lobe 6 years ago. Magnetic resonance imaging test revealed new infiltrative lesions (6.5cm) in left frontal lobe and corpus callosum, in addition to the non-enhancing mass (3.4cm). New infiltrative lesion suspected anaplastic change and the patient underwent tumorectomy. Microscopically, non-enhancing lesion showed high cellularity, moderate nuclear atypia and brisk mitosis. Microvascular proliferation and necrosis were absent that can be diagnosis as anaplastic astrocytoma. However, new infiltrative lesion showed microvascular proliferation and necrosis that acceptable for diagnosis as glioblastoma. IDH-1 immunohistochemistry (IHC) was positive in anaplastic astrocytoma but negative in glioblastoma. In addition, we assessed NGS based on the SNUBH Brain v1.0 (Macrogen, Seoul, South Korea) panel. Similar to IHC result, IDH-1 (p.Arg132His) mutation was found in anaplastic astrocytoma but not in glioblastoma. Interestingly, ATRX (p.Gln1670Ter) and TP53 (p.His193Arg) mutations were found in both lesions. Additionally, PTEN (p.His296Pro) mutation was identified in glioblastoma component only. Until now, it is well-known hypothesis that the IDH mutation initiated in glial progenitor cell and the other genetic mutations occur sequentially in pathogenesis of secondary glioblastoma. Notably, this is the first case report that other genetic alterations can be initiated before IDH mutation contrary to previous hypothesis. In our case, mutation of ATRX and TP53 might be initiated, and PTEN and IDH-1 mutations were sequentially occurred in glioblastoma and anaplastic astrocytoma, respectively.


Sign in / Sign up

Export Citation Format

Share Document